《中国期刊全文数据库》收录期刊
《中国核心期刊（遴选）数据库》收录期刊
《中文科技期刊数据库》收录期刊
外科研究与新技术（中英文）

外科研究与新技术（中英文） >

2021 , Vol. 10 >Issue 3: 203 - 208

DOI: https://doi.org/10.3969/j.issn.2095-378X.2021.03.013

综述

新型冠状病毒变异株对新型冠状病毒疾病诊治及防疫的影响分析

  • 张珂 ,
  • 沈洁 ,
  • 胡丽华
展开
  • 1.上海奥普生物医药股份有限公司,上海 201201;
    2.同济大学附属同济医院 《外科研究与新技术》编辑部,上海 200065
张珂（1983—）,男,博士,工程师,从事医疗器械研发工作

收稿日期: 2021-08-11

  网络出版日期: 2022-08-22

基金资助

上海即时检测医学工程技术研究中心（18DZ2250700）; 上海医学即时检验产业技术创新战略联盟（11DZ0512200）; 2017上海领军人才项目-李福刚（042）

收起

Impacts of SARS-CoV-2 variants on diagnosis, treatment, and control of COVID-19

  • ZHANG Ke ,
  • SHEN Jie ,
  • HU Lihua
Expand
  • 1. Shanghai Upper Bio-tech Pharma Co., Ltd., Shanghai 201201, China;
    2. Editorial Department of Surgical Research and New Technique, Tongji Hospital Affiliated to Tongji University, Shanghai 200065, China

Received date: 2021-08-11

  Online published: 2022-08-22

Fold

摘要

新型冠状病毒在全球多国陆续演变出多个变异株,传播力和危害性逐步累积增强。目前Delta变异株已侵入我国,造成了严重的危害。新冠病毒的持续变异,已成为全球关注的焦点。本文汇总分析各典型变异株的研究数据,从生物学角度探讨变异株对病原体检测、治疗、疫苗等方面的影响,以及病毒持续变异对防疫工作造成的冲击和应对策略。

关键词： 新型冠状病毒; 变异株; 突变; 诊断; 治疗; 疫苗; 疫情防控

本文引用格式

张珂 , 沈洁 , 胡丽华 . 新型冠状病毒变异株对新型冠状病毒疾病诊治及防疫的影响分析[J]. 外科研究与新技术（中英文）, 2021 , 10(3) : 203 -208 . DOI: 10.3969/j.issn.2095-378X.2021.03.013

Abstract

Multiple variants of SARS-CoV-2 have appeared in many countries across the world and resulted in the gradual enhancement of viral transmission and infection. Recently, Delta variant invaded China and caused serious consequences. The continuous mutation of SARS-CoV-2 is turning into a critical topic of global pandemic control. By summarizing the studies of typical variants, this article analyzed the impacts of SARS-CoV-2 variants on diagnosis, treatment, and vaccination from the perspective of biology, and discussed the strategies on how to tackle the challenge of the continuous mutation.

Key words： SARS-CoV-2; Variant; Mutation; Diagnosis; Treatment; Vaccine; Pandemic control

参考文献

[1] Kim D, Lee J Y, Yang J S, et al.The architecture of SARS-CoV-2 transcriptome[J]. Cell, 2020,181(4):914-921.
[2] Ferron F, Subissi L, De Morais A T S, et al. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus rna[J]. PNAS, 2018,115(2):E162-E171.
[3] Gerhard W, Mozdzanowska K, Zharikova D.Prospects for universal influenza virus vaccine[J]. Emerg Infect Dis, 2006,12(4):569-574.
[4] Laffeber C, Koning K D, Kanaar R, et al.Experimental evidence for enhanced receptor binding by rapidly spreading SARS-CoV-2 variants[J]. J Mol Biol, 2021,433(15):167058.
[5] Xie X, Liu Y, Liu J, et al.Neutralization of SARS-CoV-2 spike 69/70 deletion, e484k and n501y variants by bnt162b2 vaccine-elicited sera[J]. Nat Med, 2021,27(4):620-621.
[6] Collier D A, De M A, Ferreira I A, et al.Sensitivity of SARS-CoV-2 b.1.1.7 to mrna vaccine-elicited antibodies[J]. Nature, 2021,593(7857):136-141.
[7] Campbell F, Archer B, Laurenson-Schafer H, et al.Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021[J]. Eurosurveillance, 2021,26(24):1-6.
[8] Deng X, Garcia-Knight M A, Khalid M M, et al. Transmission, infectivity, and neutralization of a spike l452r SARS-CoV-2 variant[J]. Cell, 2021,184(13):3426-3437.
[9] Zhou B, Thao T T N, Hoffmann D, et al. SARS-CoV-2 spike d614g change enhances replication and transmission[J]. Nature, 2021,592(7852):122-127.
[10] 杨梅,张晓天,刘秀敏,等.新型冠状病毒检测方法的应用现状[J]. 中国实验诊断学, 2020,24(7):1204-1207.
[11] Karim S, Oliveira T D.New SARS-CoV-2 variants-clinical, public health, and vaccine implications[J]. New Engl J Med,2021,384(19):1866-1868.
[12] Sadoff J, Gray G, Vandebosch A, et al.Safety and efficacy of single-dose Ad26. Cov2. S vaccine against COVID-19[J]. New Engl J Med, 2021,384(23):2187-2201.
[13] Lopez Bernal J, Andrews N, Gower C, et al.Effectiveness of COVID-19 vaccines against the b.1.617.2 (delta) variant[J]. New Engl J Med, 2021,385(7):585-594.
[14] Emary K R, Golubchik T, Aley P K, et al.Efficacy of chadox1 nCOV-19 (azd1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (b.1.1.7): An exploratory analysis of a randomised controlled trial[J]. The Lancet, 2021,397(10282):1351-1362.
[15] Wang P, Nair M S, Liu L, et al.Antibody resistance of SARS-CoV-2 variants b.1.351 and b.1.1.7[J]. Nature, 2021,593(7857):130-135.
[16] Edara V V, Norwood C, Floyd K, et al.Infection-and vaccine-induced antibody binding and neutralization of the b.1.351 SARS-CoV-2 variant[J]. Cell Host Microbe, 2021,29(4):516-521.
[17] Shen X, Tang H, McDanal C, et al. SARS-CoV-2 variant b.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines[J]. Cell Host Microbe, 2021,29(4):529-539.
[18] Hoffmann M, Arora P, Groß R, et al.SARS-CoV-2 variants b.1.351 and p.1 escape from neutralizing antibodies[J]. Cell, 2021,184(9):2384-2393.
[19] Kuzmina A, Khalaila Y, Voloshin O, et al.SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera[J]. Cell Host Microbe, 2021,29(4):522-528.
[20] 穆鑫,赵颖,张兰,等.我国治疗新冠肺炎药物临床研究现状浅析[J]. 中国临床药理学与治疗学, 2020,25(8):869-877.
[21] Weinreich D M, Sivapalasingam S, Norton T, et al.Regn-cov2, a neutralizing antibody cocktail, in outpatients with COVID-19[J]. New Engl J Med, 2021,384(3):238-251.
[22] Hansen J, Baum A, Pascal K E, et al.Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail[J]. Science, 2020,369(6506):1010-1014.
[23] Kidd M, Richter A, Best A, et al.S-variant SARS-CoV-2 lineage b1. 1.7 is associated with significantly higher viral load in samples tested by taqpath polymerase chain reaction[J]. J Infect Dis, 2021,223(10):1666-1670.
[24] Rockx B, Kuiken T, Herfst S, et al.Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model[J]. Science, 2020,368(6494):1012-1015.
[25] Vogel G.Mixing vaccines may boost immune responses[J]. Science, 2021,372(6547):1138.
[26] Andersen K G, Rambaut A, Lipkin W I, et al.The proximal origin of SARS-CoV-2[J]. Nat Med, 2020,26(4):450-452.
[27] Zhou P, Yang X L, Wang X G, et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020,579(7798):270-273.
[28] Li W.Bats are natural reservoirs of SARS-like coronaviruses[J]. Science, 2005,310(5748):676-679.
[29] Azhar E I, El-Kafrawy S A, Farraj S A, et al. Evidence for camel-to-human transmission of MERS coronavirus[J]. New Engl J Med, 2014,370(26):2499-2505.
[30] Shi J, Wen Z, Zhong G, et al.Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2[J]. Science, 2020,368(6494):1016-1020.
Options
文章导航

/

〈 〉